Addex Therapeutics (NASDAQ:ADXN) Upgraded to Buy by HC Wainwright

HC Wainwright upgraded shares of Addex Therapeutics (NASDAQ:ADXN) from a neutral rating to a buy rating in a report issued on Wednesday morning, MarketBeat reports. The brokerage currently has $30.00 target price on the stock. HC Wainwright also issued estimates for Addex Therapeutics’ Q2 2024 earnings at ($0.07) EPS, Q3 2024 earnings at ($0.07) EPS, Q4 2024 earnings at ($0.07) EPS and FY2025 earnings at ($0.34) EPS.

Addex Therapeutics Stock Down 1.3 %

NASDAQ:ADXN opened at $7.90 on Wednesday. The stock’s 50 day moving average price is $8.30 and its two-hundred day moving average price is $10.81. The firm has a market capitalization of $8.37 million, a price-to-earnings ratio of -0.46 and a beta of 1.77. Addex Therapeutics has a 12-month low of $5.00 and a 12-month high of $27.90.

Addex Therapeutics (NASDAQ:ADXN) last released its quarterly earnings data on Thursday, June 6th. The company reported ($1.37) earnings per share (EPS) for the quarter. The business had revenue of $0.27 million during the quarter. Addex Therapeutics had a negative net margin of 818.50% and a negative return on equity of 364.24%. Equities research analysts expect that Addex Therapeutics will post -11.8 EPS for the current year.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.